A September Skip, The Bullish Case for Viking Therapeutics, and Lassoing the Laggards 8/19/25
19 Aug 2025
• 43 min
• EN
Why the Fed could skip a September cut altogether, despite higher inflation data. BTIG makes the case for sticking with Viking Therapeutics despite disappointing weight loss drug trial data. Plus, the laggards our traders says to buy now.
From "The Exchange"
Listen on your iPhone
Download our iOS app and listen to interviews anywhere. Enjoy all of the listener functions in one slick package. Why not give it a try?
Comments
Add comment Feedback